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Abstract
Introduction Severe sepsis and septic shock are common
problems in the intensive care unit and carry a high mortality.
Endotoxin, one of the principal components on the outer
membrane of gram-negative bacteria, is considered important to
their pathogenesis. Polymyxin B bound and immobilized to
polystyrene fibers (PMX-F) is a medical device that aims to
remove circulating endotoxin by adsorption, theoretically
preventing the progression of the biological cascade of sepsis.
We performed a systematic review to describe the effect in
septic patients of direct hemoperfusion with PMX-F on
outcomes of blood pressure, use of vasoactive drugs,
oxygenation, and mortality reported in published studies.
Methods We searched PubMed, the Cochrane Collaboration
Database, and bibliographies of retrieved articles and consulted
with experts to identify relevant studies. Prospective and
retrospective observational studies, pre- and post-intervention
design, and randomized controlled trials were included. Three
authors reviewed all citations. We identified a total of 28
publications – 9 randomized controlled trials, 7 non-randomized
parallel studies, and 12 pre-post design studies – that reported
at least one of the specified outcome measures (pooled sample
size, 1,425 patients: 978 PMX-F and 447 conventional medical
therapy).
Results Overall, mean arterial pressure (MAP) increased by 19
mm Hg (95% confidence interval [CI], 15 to 22 mm Hg; p <
0.001), representing a 26% mean increase in MAP (range, 14%
to 42%), whereas dopamine/dobutamine dose decreased by
1.8 μg/kg per minute (95% CI, 0.4 to 3.3 μg/kg per minute; p =
0.01) after PMX-F. There was significant intertrial heterogeneity
for these outcomes (p < 0.001), which became non-significant
when analysis was stratified for baseline MAP. The mean arterial
partial pressure of oxygen/fraction of inspired oxygen (PaO2/
FiO2) ratio increased by 32 units (95% CI, 23 to 41 units; p <
0.001). PMX-F therapy was associated with significantly lower
mortality risk (risk ratio, 0.53; 95% CI, 0.43 to 0.65). The trials
assessed had suboptimal method quality.
Conclusion Based on this critical review of the published
literature, direct hemoperfusion with PMX-F appears to have
favorable effects on MAP, dopamine use, PaO2/FiO2 ratio, and
mortality. However, publication bias and lack of blinding need to
be considered. These findings support the need for further
rigorous study of this therapy.
APACHE = Acute Physiology and Chronic Health Evaluation; CI = confidence interval; CO = cardiac output; DHP-PMX = direct hemoperfusion with 
polymyxin B-immobilized fiber column; EU = endotoxin units; ICU = intensive care unit; IL = interleukin; LAL = limulus amebocyte lysate; MAP = mean 
arterial pressure; MRSA = methicillin-resistant Staphylococcus aureus; PaO2/FiO2 = arterial partial pressure of oxygen/fraction of inspired oxygen; 
PMX-F = polymyxin B-immobilized fiber column; RCT = randomized controlled trial; RR = risk ratio; TNF-α = tumor necrosis factor-alpha.Critical Care    Vol 11 No 2    Cruz et al.
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Introduction
Severe sepsis and septic shock are common problems
encountered in the intensive care unit (ICU), with an estimated
incidence in the United States of 750,000 cases per year and
a mortality rate of 25% to 80% [1]. Sepsis involves a complex
interaction between bacterial toxins and the host immune sys-
tem. Bacterial-associated toxins are some of the principal
components of gram-negative (endotoxin) and gram-positive
(lipotechoic acid) organisms [2-4]. Lipotechoic acid, a product
of Staphylococcal organisms, promotes production of tumor
necrosis factor-alpha (TNF-α) and leads to the development of
sepsis and septic shock. Endotoxin, which exists in the outer
membrane of gram-negative bacteria, interacts with the host
during gram-negative sepsis. Endotoxin causes the release of
cytokines such as interleukin (IL)-1 and TNF-α and activates
complements and coagulation factors. Endotoxin is consid-
ered one of the principal biological substances that cause
gram-negative septic shock [2,4]. Nevertheless, anti-endo-
toxin drug therapies failed to demonstrate a consistent clinical
benefit: E5 murine antibody demonstrated non-specific bind-
ing/inactivation in vivo, conflicting results were seen with HA-
1A monoclonal antibody in two separate randomized control-
led trials (RCTs), and intravenous polymyxin B has significant
nephrotoxic and neurotoxic effects [4-6]. This lack of clinical
success with these anti-endotoxin therapies has shifted inter-
est to extracorporeal therapies to reduce circulating levels of
endotoxin. Polymyxin B bound and immobilized to polystyrene
fibers (PMX-F) has been reported to effectively bind endotoxin
in both in vitro and in vivo studies [7]. The rationale underlying
extracorporeal therapy with PMX-F would be to remove circu-
lating endotoxin by adsorption, thus preventing progression of
the biological cascade of sepsis. This blood purification med-
ical device has been reimbursed by the Japanese national
health insurance program since 1994 [7]. Direct hemoper-
fusion with PMX-F (DHP-PMX) can be applied to patients with
endotoxemia or suspected gram-negative infection who fulfill
the conditions of Systemic Inflammatory Response Syndrome
and have septic shock requiring vasoactive agents. Since
1994, more than 60,000 patients have received this
treatment.
Several studies demonstrate efficient removal of endotoxin
with DHP-PMX as well as suppression of Staphylococcus
aureus  lipoteichoic acid-induced TNF-α production [7-24].
However, despite the well-documented capacity to lower
blood endotoxin levels, the impact of this therapy on clinical
endpoints remains unclear. This systematic review aims to
describe the published experience with DHP-PMX as well as
the methodological quality of these studies and estimate the
magnitude of effect reported in these studies. Because PMX-
F does not directly address the source of sepsis, physiologic
endpoints such as reduction in vasopressor or ventilatory sup-
port, improvement in hemodynamics or oxygenation, and
reduction in severity scores, in addition to mortality, are out-
comes of clinical interest [25]. Therefore, the primary objective
of this systematic review is to describe the effect of PMX-F on
blood pressure, use of vasoactive drugs, oxygenation, and
mortality. A secondary objective is to describe the effect on
endotoxin levels reported in these studies.
Materials and methods
The search strategy and data abstraction were defined by a
prospective protocol. We searched PubMed, and the
Cochrane Collaboration Database through April 2006, using
the following search terms: 'hemoperfusion or hemadsorption
or hemodiafiltration or hemofiltration or hemodialysis' and 'pol-
ymyxin or polymyxin B or Toraymyxin or PMX-DHP or DHP-
PMX' without language restrictions. We also reviewed bibliog-
raphies of retrieved articles and consulted with experts to iden-
tify relevant studies. Other methods of study identification
included searching names of authors of relevant studies and
contacting industry. Published English, Japanese, and Italian
language full-text case series, cohort studies, and RCTs of
DHP-PMX were eligible. Japanese articles were translated by
a competent scientific/medical translator with a knowledge of
the subject matter. To further facilitate translation, the transla-
tor was given instructions regarding the specific data being
abstracted as well as specific statements of interest to the
reviewers (for example, regarding randomization, blinding, and
follow-up).
Prospective and retrospective observational studies, pre- and
post-intervention design, and RCTs reporting original data on
five or more adults treated with PMX-F for sepsis were
included. Three authors reviewed all citations and abstracted
data independently on a standardized form, and disagree-
ments were resolved by discussion. Included trials had at least
one of the following outcome measures: mean arterial pres-
sure (MAP), doses of vasoactive agents, arterial partial pres-
sure of oxygen/fraction of inspired oxygen (PaO2/FiO2) ratios,
endotoxin levels, and mortality. We contacted authors and
invited them to provide data for inclusion in the meta-analysis
if we were unable to extract data directly from the publication
or when relevant data were presented only in graphical form or
only as subgroups (for example, survivors and non-survivors,
by levels of Acute Physiology and Chronic Health Evaluation
[APACHE] score). If the authors did not provide the data,
these studies were excluded.
If multiple publications by the same investigator existed, the
studies were reviewed carefully and/or the investigator was
contacted to ensure that no data were analyzed in duplicate.
At least three attempts were made to contact the correspond-
ing and/or first investigator. Methods included e-mail and
mailed letters. Three investigators independently assessed
trial quality with the validated scale by Jadad and colleagues
[26], which measures blinding, randomization, withdrawals,
and dropouts. A maximum score of 5 represents the highest
quality trial.Available online http://ccforum.com/content/11/2/R47
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The primary endpoints were change in MAP, use of vasoactive
agents and PaO2/FiO2 ratio at the end of DHP-PMX, and mor-
tality. A secondary endpoint was the change in endotoxin lev-
els after DHP-PMX. Assuming a standard deviation of 20 mm
Hg for MAP pre- and post-PMX-F, a sample size of at least 70
patients would be needed to detect a change in MAP of at
least 10 mm Hg in a paired analysis. For continuous variables
such as blood pressure, data in the published studies gener-
ally were presented as a pooled summary of pre-PMX-F treat-
ment versus post-PMX-F treatment rather than PMX-F versus
conventional therapy. In many of the parallel studies, 'post-
conventional therapy' values were not reported for this group.
Therefore, for continuous outcomes, the effect size was the
change (follow-up minus baseline) for each parameter in
patients treated with PMX-F. The 'post-PMX-F' values used for
the analyses were those 24 to 48 hours after the last PMX-F
treatment. We combined data from parallel-designed trials
with those from 'pre-post' studies in a meta-analysis using the
generic inverse variance method. In both types of studies, we
recorded the mean change from baseline values for the PMX
group and variance estimates for this change, when reported.
When these were not reported, we attempted to obtain these
values or paired individual data directly from the authors. Not
all investigators provided the information requested. For the
studies in which these data were not available, we calculated
these values as the difference between the mean 'pre-PMX-F'
and 'post-PMX-F' values, and their variance estimates were
derived from confidence intervals (CIs), standard deviations,
and probability values reported in the manuscript [27]. Among
the studies in which 'pre-PMX-F,' 'post-PMX-F,' and change
variance estimates were available, the median correlation
between the two periods was 0.59 (range, 0.05 to 0.93). To
be conservative, we assumed a correlation of 0.5 to impute
missing change variance estimates in the primary analysis. We
performed sensitivity analyses of this choice of correlation,
using 0.05 as the most conservative estimate, and the results
remained robust. With regard to the endpoint of mortality,
because DHP-PMX is an invasive and costly procedure, we
considered it acceptable as a treatment for sepsis if a 15%
absolute risk reduction could be achieved. Assuming a 50%
mortality in the conventional medical therapy group, an α of
0.05, and 80% power, a sample size of at least 182 subjects
in each arm is needed for parallel studies. Studies were con-
sidered for inclusion in the mortality analysis if they reported
mortality for a comparable patient group (for example, sepsis)
in the ICU which was not treated with PMX-F. Death was
determined at the end of follow-up (14 to 60 days), as availa-
ble. Results for mortality were combined on the risk ratio (RR)
scale. Because the random effects model incorporates statis-
tical heterogeneity and provides a more conservative estimate
of the pooled effect size than a fixed model, we present the
results of all analyses according to a random model. Intertrial
heterogeneity was estimated by chi-square test. Sensitivity
analyses were predefined a priori to evaluate the effects of
study design, sample size, type of infection (gram-positive or -
negative), imputed values for the correlation coefficient (dis-
cussed above), and center duplication. Because some investi-
gators had more than one publication, for each endpoint we
performed a sensitivity analysis in which we included only one
study per investigator group, selecting the study with the larg-
est sample size. We also assumed that the magnitude of
change in certain clinical parameters would be dependent on
the baseline value and performed a sensitivity analysis based
on baseline blood pressure, PaO2/FiO2 ratio, and endotoxin
levels. Funnel plots were drawn to examine whether the
smaller studies in the meta-analysis tended to show larger
treatment effects, which might be due to publication bias.
Analyses were performed with Review Manager version 4.2
(RevMan; The Cochrane Collaboration 2003, Nordic
Cochrane Centre, Copenhagen, Denmark). The level of statis-
tical significance is set at a P value of less than 0.05. For con-
tinuous outcomes, the changes in the parameter (for example,
MAP) are expressed in their original linear scale as a point esti-
mate with 95% CIs and P value. For mortality, values for RR
are expressed as a point estimate with 95% CIs and P value.
All RRs refer to the risk for the PMX group compared with the
conventional medical therapy group (labeled in graphs as
'PMX' and 'Conventional,' respectively).
Results
Identification of eligible trials
One hundred fifty-nine abstracts were reviewed. Of these, 106
articles were deemed worthy of further exploration and review
(Figure 1). Potentially relevant Japanese articles were trans-
lated to assess for inclusion. On careful review and confirma-
tion with authors, all were found to have patient overlap with
subsequent publications by the same authors in English lan-
guage journals and were excluded for this reason. We identi-
fied a total of 28 publications as relevant to this review (Tables
1 and 2). Of these, 16 parallel trials (9 RCT and 7 non-RCT)
and 12 pre-post cohort studies reported at least one of the
necessary outcome measures and were included in the analy-
sis (pooled sample size for parallel studies = 1,040 [RCT =
474], for pre-post studies = 385).
Methodological quality of included studies
Three independent reviewers allocated a score of methodo-
logical quality. There was no disagreement between reviewers
in any case. Overall, study quality was poor (Jadad scores of
less than 3). Among the randomized studies, allocation con-
cealment was deemed adequate in three trials [8,9,28] and
uncertain in six [10-15]. Randomization was not performed in
seven of the parallel-design studies [19,21,29-33]. Like most
trials on extracorporeal therapies, none of the studies was
double-blinded. Although very few studies had a specific
statement on loss of follow-up (which merits 1 point on the
Jadad scale), it was generally clear from the presented data
that all patients were accounted for in terms of mortality in
these short-term studies.Critical Care    Vol 11 No 2    Cruz et al.
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Characteristics of patients and interventions
The 28 trials included 1,425 patients: 978 in the PMX-F group
and 447 in the conventional medical therapy group. Of these,
26 studies reported the mean age of the patients (range, 39 to
78.5 years), 26 reported the proportion of men (range, 20% to
85.7%), and 23 reported the baseline severity of illness at the
time of enrollment as APACHE II score (range, 8.8 to 28.5
points). Characteristics of the included studies are shown in
Tables 1 and 2. Two RCTs enrolled patients with methicillin-
resistant S. aureus (MRSA) infections [8,12]. When reported,
gram-negative infections were identified in 71% of patients
(range, 37.9% to 100% in individual studies) [10,11,13-
17,21-24,28-30,32,34-38].
DHP-PMX was performed with an adsorbent column that was
designed for clinical use and that contained 5 mg of PMX per
gram of polystyrene fiber and with a priming volume of 135 ml
(Toray Industries, Inc., Tokyo, Japan) [7,39]. The usual
indication for DHP-PMX was sepsis (with or without septic
shock) as defined by the American College of Chest Physi-
cians/Society of Critical Care Medicine Consensus Confer-
ence Committee [40]. DHP-PMX was performed for two hours
at a blood flow rate of 50 to 150 ml/minute, once
[15,21,28,30-32,34] or a maximum of two [8,9,11-14,16-
20,22-24,29,33,35] or three [38] times, depending on the
clinical response of the patient. When necessary, the suc-
ceeding PMX-F treatment was performed 24 hours after the
previous treatment. Nafamostat mesilate and unfractionated or
low-molecular-weight heparin were used as the anticoagulant
[13-16,18,21-24,28,29,33-36,38]. The type of anticoagulant
was not specified in other studies [8-12,17,19,20,30-32,37].
DHP-PMX was performed in addition to conventional medical
therapy, which included antibiotic therapy, administration of
gamma-globulins, vasopressors, hemodynamic monitoring,
organ support in the ICU including mechanical ventilation, cor-
rective measures for metabolic abnormalities [8-
15,23,29,35,38], and surgery when appropriate [28,31]. In
five studies, renal replacement therapy [9,15,22,23,38] was
also performed for renal failure. One study specifically enrolled
patients with acute renal failure [15] and another, chronic renal
failure [22].
Table 1
Characteristics of included studies: parallel-design studies



















Tani et al. [21] (a)a 1998 Japan No 33 69.7 SSS 39.1 N/A 37 78.4 SSS 46.2 N/A
Nakamura et al. [10] 1999 Japan Yes 20 60.0 NS N/A 30 60.0 24.8 52.6
Nemoto et al. [14] 2001 Japan Yes 44 61.4 23 46.0 54 64.7 22 42.4
Nakamura et al. [11] (a) 2002 Japan Yes 9 66.7 27.5 62.2 9 66.7 28.5 65.6
Suzuki et al. [15] 2002 Japan Yes 24 70.8 25 53.3 24 75.0 25 53.3
Tsushima et al. [33] 2002 Japan No 10 80.0 NS N/A 24 70.8 22.4 43.9
Tsugawa et al. [31] 2002 Japan No 51 43.1 NS N/A 31 45.2 NS N/A
Nakamura et al. [8] (b) 2003 Japan Yes 10 60.0 27 60.5 10 60.0 27.6 62.5
Nakamura et al. [12] (c) 2003 Japan Yes 25 64.0 23 46.4 35 68.6 24.2 50.4
Nakamura et al. [29] (d) 2003 Japan No 108 62.0 24 49.7 206 64.1 24.6 51.9
Nakamura et al. [13] (e) 2004 Japan Yes 10 60.0 28 63.9 15 60.0 28.4 65.2
Nakamura et al. [9] (f) 2004 Japan Yes 50 64.0 24.8 52.6 70 61.4 25.4 54.8
Ono et al. [30] 2004 Japan No 13 61.5 8.8 9.7 10 60.0 19.6 34.2
Tsujimoto et al. [32] 2004 Japan No 10 20.0 10.6 12.2 7 85.7 19.4 33.5
Nakamura et al. [19] (g) 2005 Japan No 12 58.3 25 53.3 14 64.3 25.5 55.1




Yes 18 47.4 18.7 31.3 17 76.5 16.7 25.4
Total 447 593
aTwo studies reported severity of illness as SSS rather than APACHE score.
APACHE II score expressed as the mean. Predicted mortality was calculated as eLogit/(1+ eLogit), where Logit = -3.517 + (APACHE II) × 0.146. APACHE, Acute 
Physiology and Chronic Health Evaluation; N/A, not applicable; NS, not stated; PMX-F, polymyxin B-immobilized fiber column; SSS, Sepsis Severity Score.Available online http://ccforum.com/content/11/2/R47
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Effects on MAP and dose of vasoactive agents
The effect of PMX-F therapy on MAP was ascertained in a
pooled analysis of 12 studies (2 RCT, 4 non-RCT, and 6 pre-
post; 275 patients) [15,18,21-23,28,30,32-34,37,38]. The
method of measuring blood pressure was not specified in any
of the articles. All studies that provided sufficient data reported
improvement in MAP after PMX-F (Figure 2a). The pooled
estimate showed that PMX-F was associated with a significant
increase in MAP (weighted mean difference, 19 mm Hg; 95%
CI, 15 to 22 mm Hg; p < 0.001). This represented a 26%
mean increase in MAP (range, 14% to 42%). However, inter-
trial heterogeneity in this primary analysis was significant (p <
0.001). Because the magnitude of change in blood pressure
would be dependent on the baseline value, subgroup analysis
was performed based on the mean pre-PMX MAP in the PMX-
F group (Figure 2a). Patients with a mean pre-PMX MAP
below 70 mm Hg had a greater improvement in MAP (26 mm
Hg) compared to those with a mean pre-PMX MAP of at least
70 mm Hg (16 mm Hg). Selected sensitivity analyses are
shown in Table 3. Intertrial heterogeneity became non-signifi-
cant when the analysis was limited to subgroups defined by
pre-PMX MAP; however, there was still substantial heteroge-
neity (45.6%) in the subgroup with greater than or equal to 70
mm Hg (Figure 2a).
In critically ill patients, it is often difficult to interpret blood pres-
sure in isolation because vasoactive agents can be manipu-
lated to alter the blood pressure. In four studies, the dose of
dopamine or dobutamine or the average of the sum of the two
was reported [15,22,24,37]. All studies showed a trend
toward a decrease in the dose after PMX-F (Figure 2b). Over-
Table 2
Characteristics of included studies: pre-post design studies
Study Year Country of origin N Percentage of males APACHE II score Predicted mortality (percentage)
Nakamura et al. [16] (h) 1998 Japan 24 58.3 26.8 59.8
Nakamura et al. [17] (i) 1998 Japan 17 58.8 23.1 46.4
Shimada et al. [20] 2000 Japan 40 NS NS N/A
Tani et al. [36] (b) 2001 Japan 88 71.6 24.2 50.4
Uriu et al. [24] 2002 Japan 24 66.7 NS N/A
Ikeda et al. [34] 2004 Japan 66 NS 26.2 57.6
Nakamura et al. [18] (j) 2004 Japan 12 66.7 24.5 51.5
Tojimbara et al. [22] 2004 Japan 24 45.8 21.4 40.3
Kushi et al. [35] 2005 Japan 36 58.3 24 49.7
Ueno et al. [23]a 2005 Japan 16 31.3 SSS 32 N/A
Kojika et al. [37] 2006 Japan 24 62.5 14.2 19.1
Casella et al. [38] 2006 Italy 14 57.1 26.5 58.7
Total 385
aTwo studies reported severity of illness as SSS rather than APACHE score.
APACHE II score expressed as the mean. Predicted mortality was calculated as eLogit/(1 + eLogit), where Logit = -3.517 + (APACHE II) × 0.146. 
APACHE, Acute Physiology and Chronic Health Evaluation; N/A, not applicable; NS, not stated; SSS, Sepsis Severity Score.
Figure 1
Details of included and excluded trials Details of included and excluded trials. MAP, mean arterial pressure; 
PaO2/FiO2, arterial partial pressure of oxygen/fraction of inspired 
oxygen.Critical Care    Vol 11 No 2    Cruz et al.
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Table 3
Selected sensitivity analysis




Change in MAP (mm Hg)
All 12 275 19 (15, 22) < 0.001 < 0.001
n > 20 5 175 18 (13, 22) < 0.001 < 0.001
Pre-PMX MAP < 70 3 41 26 (22, 30) < 0.001 0.85
Pre-PMX MAP ≥ 70 9 234 16 (13, 18) < 0.001 0.07
Center duplication 11 268 18 (15, 21) < 0.001 < 0.001
Change in dopamine/dobutamine dose (μg/kg per minute)
Alla 4 96 -1.8 (-3.3, -0.4) 0.01 < 0.001
Pre-PMX MAP <70 1 24 -5.0 (-6.6, -3.4) < 0.001 N/A
Pre-PMX MAP ≥ 70 3 72 -0.8 (-1.2, -0.4) < 0.001 0.33
Change in PaO2/FiO2 ratio (Units)
Alla 7 151 32 (23, 41) < 0.001 0.87
Pre-PMX PaO2/FiO2 ratio < 200 2 36 30 (19, 40) < 0.001 0.62
Pre-PMX PaO2/FiO2 ratio ≥200 5 115 40 (20, 60) < 0.001 0.84
Change in endotoxin level (pg/ml)
All 17 455 -21.2 (-24.9, -17.5) < 0.001 < 0.001
Excluding MRSA 15 410 -24.1 (-28.0, -20.2) < 0.001 < 0.001
Pre-PMX endotoxin <30 pg/ml 5 97 -9.8 (-12.1, -7.5) < 0.001 0.007
Pre-PMX endotoxin ≥30 pg/ml 12 358 -28.2 (-32.3, -24.1) < 0.001 < 0.001
Pre-PMX endotoxin <40 pg/ml 10 283 -14.9 (-18.7, -11.1) < 0.001 < 0.001
Pre-PMX endotoxin ≥40 pg/ml 7 172 -37.4 (-41.9, -32.8) < 0.001 0.25
Center duplication 6 225 -16.4 (-24.0, -8.9) < 0.001 < 0.001
Mortality Risk ratio
All 15 920 0.53 (0.43, 0.65) < 0.001 0.07
RCT 8 354 0.50 (0.37, 0.68) < 0.001 0.12
Parallel non-RCT 7 566 0.55 (0.38, 0.81) 0.002 0.07
Excluding MRSA 13 840 0.55 (0.44, 0.69) < 0.001 0.08
RCT excluding MRSA 6 274 0.55 (0.40, 0.76) < 0.001 0.2
n > 20 7 722 0.56 (0.46, 0.68) < 0.001 0.17
APACHE II score < 25 9 713 0.56 (0.43, 0.73) < 0.001 0.06
APACHE II score ≥ 25 6 207 0.45 (0.30, 0.68) < 0.001 0.25
28- to 30-day mortality only 9 704 0.54 (0.43, 0.68) < 0.001 0.12
Center duplication 8 673 0.61 (0.46, 0.82) 0.001 0.03
aFor outcomes of dopamine/dobutamine dose and PaO2/FiO2 ratio, all included studies had a sample size greater than 20. APACHE, Acute 
Physiology and Chronic Health Evaluation; CI, confidence interval; MAP, mean arterial pressure; MRSA, methicillin-resistant Staphylococcus 
aureus; N/A, not applicable; PaO2/FiO2, arterial partial pressure of oxygen/fraction of inspired oxygen; PMX, polymyxin B-immobilized fiber 
column; RCT, randomized controlled trial.Available online http://ccforum.com/content/11/2/R47
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all, the dose was decreased by 1.8 μg/kg per minute (95% CI,
0.4 to 3.3 μg/kg per minute; p = 0.01). In these studies, there
was also an increase in mean MAP after PMX-F (range, 16 to
28 mm Hg).
Effects on PaO2/FiO2 ratio
The effect of PMX-F therapy on PaO2/FiO2 was ascertained in
a pooled analysis of seven studies [18,22,28,33,35,37,38]
(151 patients), only one of which was an RCT [28]. Overall,
the PaO2/FiO2 ratio increased by 32 units (95% CI, 23 to 41
units; p < 0.001) after PMX-F. Intertrial heterogeneity was not
significant. In the single RCT in this analysis [28], there was a
non-significant trend toward an improvement in PaO2/FiO2
ratio in the PMX-F group (delta PaO2/FiO2 ratio 29.54 versus
0.43 units in the PMX-F and control groups, respectively; p =
not significant).
Effects on mortality
Data on mortality, variably reported as 14-day [21], 28-day
[14,15,19,28,29,32], 30-day [10,31,33], and 60-day [12],
were available from 11 studies. Mortality was reported but
length of follow-up was not clearly stated in another four stud-
ies [8,11,13,30] (for a total of 15 studies: 8 RCT and 7 non-
RCT; 920 patients). One study had sepsis patients in the con-
ventional therapy group and septic shock patients in the PMX-
F group [30]. Pooled mortality rates were 61.5% in the con-
ventional therapy group and 33.5% in the PMX-F group. In the
pooled estimate, PMX appeared to significantly reduce
mortality compared with conventional medical therapy (Figure
3) (RR, 0.53; 95% CI, 0.43 to 0.65). The results were similar
between RCT and non-RCT and when two RCTs enrolling
patients with MRSA infections were excluded (RR, 0.55; 95%
CI, 0.40 to 0.76; Table 3). When the analysis was limited to
the nine studies that reported 28- to 30-day mortality
[10,14,15,19,28,29,31-33], results were unchanged. Various
sensitivity analyses are shown in Table 3. The funnels plots of
standard error against effect size for MAP and mortality are
shown in Figure 4. For MAP (Figure 4a), the effect size of
RCTs was smaller than in non-randomized parallel or pre-post
studies. For mortality (Figure 4b), three small studies (n = 17
to 35) had point estimates for RR of greater than 1.
Effects on endotoxin levels
In 19 studies (9 RCTs, 2 parallel non-RCTs, and 8 pre-post),
data on endotoxin levels were available [8-24,28,37]. In 17 of
these [8-24], endotoxin levels were measured by the
Endospecy method (upper limit of normal is 9.8 pg/ml; Seika-
gaku Corporation, Tokyo, Japan) [39]. In one study [28],
endotoxin was measured with the modified limulus amebocyte
lysate (LAL) assay by means of a commercial kit (COATEST;
DiaPharma Group, Inc., West Chester, OH, USA), which is
sensitive up to 0.05 endotoxin units [EU]/ml in serum or
plasma. In another [37], it was measured by kinetic turbidimet-
ric limulus assay by means of MT-251 Toxinometer (Wako
Pure Chemicals Industries, Ltd., Osaka, Japan), which is sen-
sitive up to 0.01 pg/ml. For consistency, we limited our analy-
sis to the studies that used the Endospecy method (n = 17
studies, 455 patients). In one of these studies, the authors
reported endotoxin levels only for patients with gram-negative
infections [22]. The pooled estimate showed that endotoxin
levels decreased by 21.2 pg/ml (95% CI, 17.5 to 24.9 pg/ml)
after PMX-F, representing a decrease of 33% to 80% from
pre-PMX levels. Results were similar when the analysis
excluded two RCTs [8,12] on MRSA infections (Table 3).
There was significant intertrial heterogeneity for this outcome
(p < 0.001). After exclusion of a trial with large standard devi-
ation [21] in a post hoc sensitivity analysis, results were
unchanged and intertrial heterogeneity remained significant (p
< 0.001). Various sensitivity analyses, including stratification
by pre-PMX endotoxin levels, did not qualitatively alter results
(Table 3). As expected, the baseline endotoxin levels were
lower in the two trials enrolling patients with MRSA infections
[8,12]. To evaluate the effect of over-representation of two
centers representing several of the 17 studies included in the
meta-analysis, we also performed a sensitivity analysis in
which we used only the study with the largest sample size from
these centers [9,14], and the results were qualitatively similar.
In the Japanese study which used the turbidimetric limulus
assay, mean endotoxin levels decreased significantly from
8.84 to 2.11 pg/ml [37] after PMX-F, whereas in the European
RCT in which endotoxin was measured with the modified LAL
assay, endotoxin levels did not change significantly (median,
28 EU pre-PMX-F to 38.5 EU 24 hours post-PMX) [28].
Adverse events
Only two studies reported adverse events, and these included
clotting of the device in 4/21 filter cartridges [28] and hyper-
sensitivity (erythema) in 2/35 patients [8]. Specifically, no
adverse events indicative of nephrotoxicity (including cellular
casts) or neurotoxicity (including irritability and progressive
weakness) were reported in any of the studies. A third study
stated that there were no adverse events related to DHP-PMX
[38].
Discussion
This systematic review of 28 published studies, which
included more than 1,400 patients treated in seven countries,
suggested multiple beneficial benefits of direct hemoperfusion
with PMX-F as compared with conventional medical therapy
for patients with sepsis and septic shock. The positive effects
are thought to be due to reductions in endotoxin levels by
DHP-PMX. Both the data from individual studies and the com-
bined data suggest that PMX-F increases blood pressure,
reduces use of vasoactive agents, and lowers endotoxin levels
as measured by the Endospecy method. The pooled estimate
also suggests that PMX-F improves gas exchange, as repre-
sented by the PaO2/FiO2 ratio, although the single RCT that
reported this outcome showed only a non-significant positive
trend [28]. In addition, there appeared to be an appreciable
effect on mortality. However, these findings must be inter-Critical Care    Vol 11 No 2    Cruz et al.
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preted with caution because overall study quality was subop-
timal and very few of these studies were planned or powered
to specifically assess mortality. The invasive nature of DHP-
PMX-F makes an absolute risk reduction of mortality by 15%
acceptable. This systematic review had adequate power to
detect a risk reduction of this magnitude.
Our analysis of hemodynamic effects of PMX-F was limited to
MAP and vasopressor use. Individual studies have reported
improvement in systemic vascular resistance
[18,21,24,41,42], cardiac output (CO), or cardiac index
[24,42] in certain patient subgroups. Unfortunately, there were
insufficient pooled data on these outcomes for meta-analysis.
Nevertheless, pooled data seem to indicate that PMX-F ther-
apy increases blood pressure while simultaneously reducing
the dose of vasoactive agents [15,22,24,37], strongly sug-
gesting a clinically significant improvement in hemodynamic
status.
We cannot conclude from our analysis whether the beneficial
clinical effects are directly related to removal of endotoxin or
perhaps other substances in the circulation. Reduced levels of
other mediators such as IL-6 [15,30,36], IL-10 [30,36], IL-18
[10], TNF-α [34,36], metalloproteinase-9 [18], plasminogen
activator inhibitor-1 [34-36,43], neutrophil elastase [35,44],
platelet factor-4 [10], β-thromboglobulin [10], soluble P selec-
tin [10], and endogenous cannabinoids [45] such as ananda-
mide have also been reported after DHP-PMX. Work by Uriu
and colleagues [24] suggests that reduction in blood endo-
toxin concentration by PMX-F therapy positively correlated
with the reduction in CO, regardless of the causative
organism.
Potential adverse events with this treatment include thrombo-
cytopenia and hypotension during DHP-PMX as well as the
known nephrotoxic and neurotoxic effects of polymyxin B. The
latter two are theoretically avoided because the polymyxin B is
Figure 2
(a) Change in MAP after PMX-F (275 participants included) (a) Change in MAP after PMX-F (275 participants included). (b) Change in dopamine/dobutamine dose after PMX-F (96 participants included). CI, 
confidence interval; MAP, mean arterial pressure.Available online http://ccforum.com/content/11/2/R47
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not released into the circulating blood. Very few adverse
events were reported among the included publications, sug-
gesting that the treatment is generally well tolerated. However,
the authors concede that small sample sizes would greatly
impair the ability to observe rare but significant adverse
effects.
A major potential source of bias in systematic reviews is that
trials with positive results are more likely to be published than
trials with negative or neutral results. In Japan, where PMX-F
has been available for more than 10 years, the results of only
a fraction of the patients treated with PMX-F have been pub-
lished. The results of any review are also inherently limited by
the quality of the primary studies. For the outcomes of
dopamine/dobutamine dose and PaO2/FiO2 ratio, there was
only a single RCT among the analyzed studies. To address
this, we performed a limited number of predefined various sen-
sitivity analyses (Table 3), and the overall effect sizes were still
significant. Most reported comparisons in the literature were
pre-treatment versus post-treatment in the PMX-F group only.
We therefore chose to analyze continuous outcomes only
within the PMX-F group rather than make a direct comparison
between PMX-F versus conventional therapy. Other interven-
tions performed in routine intensive care besides host and dis-
ease factors certainly change these variables, making the
interpretation of the positive variation (as we have found) diffi-
cult to definitively ascribe to PMX-F. Although this is not the
ideal method for determining the true effects of PMX-F, it was
thought to adequately represent the published data. Neverthe-
less, this approach will always tend to show a bias toward
improvement because the data will tend to over-represent the
survivors, particularly in a high-mortality disease such as sep-
sis. The 'post-PMX-F' values used in the analysis were those
obtained 24 to 48 hours after the last treatment. It is not clear
whether deaths occurred predominantly within this short time
frame or later. Therefore, the results of these analyses should
be interpreted with caution, and prospective validation is
needed before causal inferences can be made. Although it
may be reasonable to question the wisdom, and indeed the
validity, of mathematically combining results from such stud-
ies, the authors felt that such an attempt was warranted, at the
very least to provide a crude estimate of the likely effect of
PMX-F for the specified outcomes. The overall mortality of
61.5% observed in the conventional therapy group was com-
parable to values observed in a French multicenter study on
moderate-dose corticosteroid therapy (63%) [46] and a Bra-
zilian study on protective ventilation (71%) [47] and was
higher than those reported in studies on early goal-directed
therapy (46.5%) [48] and activated protein-C (30.8%) [49].
Moreover, mortality in the conventional therapy group within
the various studies averaged 58% (range, 0% to 88.6%),
which was higher than the predicted mortality based on
APACHE II scores (mean, 45.1%; range, 9.7% to 63.9%).
Another potential issue is that of multiple publication bias.
However, in addition to carefully reviewing the articles, we
made every effort to contact authors about this and were able
to confirm with two sets of authors with multiple publications.
We also performed sensitivity analyses to estimate the effect
of over-representation of data from centers with several publi-
cations. Nevertheless, all but two of the included studies come
from 12 groups in Japan, and the generalizability of these find-
ings ultimately will require further study. Only one RCT has
Figure 3
Risk ratio (RR) for death after polymyxin B-immobilized fiber column (PMX-F) treatment (920 participants included in meta-analysis) Risk ratio (RR) for death after polymyxin B-immobilized fiber column (PMX-F) treatment (920 participants included in meta-analysis). CI, confidence 
interval.Critical Care    Vol 11 No 2    Cruz et al.
Page 10 of 12
(page number not for citation purposes)
been performed outside Japan [28], and its findings are in con-
trast with those performed in Japan (Figure 3), highlighting
concerns about the generalizability and reproducibility of such
studies outside this setting. It is worth noting, however, that
this European RCT enrolled patients with lower APACHE
scores (Table 1) compared to the Japanese RCTs and had a
relatively small sample size. Although it is acknowledged that
patient and physician blinding is difficult to achieve in control-
led studies of extracorporeal therapies, it was generally not
stated in any of the studies whether the data analyst was
blinded to the groupings. As with several studies in the critical
care arena, the focus of publications is usually on short-term
outcomes, and it is impossible to comment on the long-term
effects of PMX-F. Lastly, the available data do not allow us to
comment on the optimal timing for PMX-F therapy.
Conclusion
Putting these data into perspective, this systematic review of
the published literature found positive effects of PMX-F on
MAP and dopamine/dobutamine use, PaO2/FiO2 ratio, endo-
toxin removal, and mortality. Overall, however, the analyzed
studies were of suboptimal quality, which may exaggerate the
magnitude of these effects. These putative benefits remain to
be determined definitively in a prospective trial with appropri-
ate clinical endpoints. Because there seemed to be beneficial
effects even among patients with gram-positive infections
such as MRSA, further investigations on this group of patients
and those with mixed infections would be worthwhile. With the
recent availability of commercial kits that are able to accurately
measure endotoxin in blood [2], trial enrollment on the basis of
endotoxin level rather than a documented type of organism or
presence of clinical signs of septic shock may allow investiga-
tors to better evaluate the effects of early treatment with PMX-
F. Certainly, additional work on the optimal timing of PMX-F
treatment is needed. Our analysis of PaO2/FiO2 ratio also sug-
gests a possible benefit in adult respiratory distress syndrome
or acute lung injury and a need for further studies in this
regard. The effect of this therapy on the development of acute
kidney injury and the need for renal replacement therapy,
which is associated with a high mortality, is another area for
further study.
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